Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR0410 Safety and PK in Hemodialysis Participants
NCT03857568Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Apr 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pruritus comparing SHR0410 group with Placebo (2 arms). Primary endpoints: Incidence of Adverse events in terms of changes in Hematology at 14 days, Incidence of Adverse events in terms of changes in Urinalysis at 14 days and 2 more. Started Apr 2019; status: completed.
02
Drugs
SHR0410
03
Conditions
pruritus
Beyond the preview
Go deeper on NCT03857568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03857568.